Experimental: ALX148 + Doxorubicin (PLD) + Pembrolizumab
Given on Day 1 of each 21 day cycle, in the following order of administration:
200 mg IV pembrolizumab* (maximum of 2 years (approximately 35 cycles)
45 mg/kg IV ALX148
30 mg/m^2 IV doxorubicin (Pegylated Liposomal Doxorubicin (PLD)*
*standard of care
A type of immunotherapy that stimulates the body’s immune system to fight cancer cells by targeting and blocking PD-1 proteins on the surface of certain immune T-cells, thus triggering the T-cells to find and kill cancer cells.
Other Name: Keytruda®
A fusion protein comprised of a high affinity CD47 blocker linked to an inactive immunoglobulin Fc region, enhancing innate and adaptive immune responses against cancer.
Other Name: evorpacept
An anthracycline that slows/stops the growth of cancer cells by blocking an enzyme called topo isomerase 2, used as second line non-platinum chemotherapy in patients with platinum-resistant ovarian cancer.
Other Name: (Pegylated Liposomal Doxorubicin (PLD)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.